New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
13:03 EDTOGXI, ATHX, ETP, SUSS, FRX, FURX, SI, GE, TWC, CMCSA, CHTR, BAC, BMY, PFE, AZNOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday amid news of a number of completed, contemplated and rejected merger and acquisition deals, highlighted by a potential blockbuster in the pharmaceutical industry. The averages opened higher though have turned mixed by midday, with the Dow leading and the Nasdaq lagging. Shares of Bank of America (BAC) have weighed on the banking sector after the company suspended its capital plans in order to boost its regulatory capital amounts and ratios after finding errors in the data the bank had previously submitted to the Federal Reserve. ECONOMIC EVENTS: In the U.S., the National Association of Realtors' pending home sales index rose 3.4% to 97.4 in March, topping expectations for a more modest 1.0% advance from the prior month. Also, the U.S. and Europe imposed more sanctions against Russia over its alleged intervention in Ukraine. COMPANY NEWS: Shares of U.K.-based drugmaker AstraZeneca (AZN) surged 13% after Pfizer (PFE) confirmed it proposed to buy its peer for nearly $100B in cash and stock. AstraZeneca revealed that its board concluded that the proposal "very significantly" undervalued the company and Pfizer said it is currently considering its next steps, but would still like to pursue some kind of mutually beneficial deal. Analysts at Jefferies said they expect Pfizer to up its bid for AstraZeneca and believe Astra will see "significant additional pressure" to engage in merger talks now that Pfizer has come public. The firm views Bristol-Myers (BMY) as another takeover option for Pfizer, but notes such a deal does not offer the tax incentives that AstraZeneca provides... Charter (CHTR) rose almost 6% after striking a deal to acquire approximately 1.4M existing Time Warner Cable (TWC) subscribers after that company completes its previously announced merger with Comcast (CMCSA). In addition, Charter will form a new holding company that will own 100% of Charter and acquire an approximate 33% stake in a new publicly-traded cable provider to be spun-off by Comcast serving approximately 2.5M customers... After General Electric (GE) made an offer to purchase the energy assets of France's Alstom (ALSMY), German industrial conglomerate Siemens (SI) confirmed it will convene "as soon as possible" after have the opportunity to meet with France's president and other high-ranking French political leaders to decide how to proceed with a competing offer... Shares of Bank of America fell more than 5% after the bank lowered its previously disclosed regulatory capital amounts and ratios due to a newly discovered accounting error, after which the Federal Reserve Board directed the company to resubmit its requested capital actions. At the Fedís request, the company has suspended its previously announced 2014 capital actions, including the $4.0B common stock repurchase authorization and the planned increase in the quarterly common stock dividend to 5c per share from 1c. MAJOR MOVERS: Among the notable gainers were two other companies that did agree to be acquired. Susser Holdings (SUSS) rose 36% after reaching a deal to be bought by Energy Transfer Partners (ETP) in a unit and cash transaction valued at a total consideration of approximately $1.8B, while Furiex Pharmaceuticals (FURX) jumped 30% after agreeing to be purchased by Forest Laboratories (FRX) for $95 per share and up to $30 per share in a contingent value right based on the success of a particular drug candidate. Among the noteworthy losers was Athersys (ATHX), which plunged 56% after its MultiStem therapy failed to show meaningful benefit in a phase 2 clinical study. Also lower following its own disappointing news from a drug trial was OncoGenex Pharmaceuticals (OGXI), which fell 55% after top-line results indicated its therapy did not result in a statistically significant improvement in overall survival in men with a certain type of prostate cancer. INDEXES: Near midday, the Dow was up 45.51, or 0.28%, to 16,406.97, the Nasdaq was down 32.15, or 0.79%, to 4,043.41, and the S&P 500 was down 0.96, or 0.05%, to 1,862.44.
News For AZN;PFE;BMY;BAC;CHTR;CMCSA;TWC;GE;SI;FURX;FRX;SUSS;ETP;ATHX;OGXI From The Last 14 Days
Check below for free stories on AZN;PFE;BMY;BAC;CHTR;CMCSA;TWC;GE;SI;FURX;FRX;SUSS;ETP;ATHX;OGXI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
September 9, 2014
06:25 EDTGEGeneral Electric to focus on finance, industrial equipment, WSJ reports
Subscribe for More Information
September 8, 2014
17:31 EDTCHTRCharter issues statement regarding STAVRA proposal
Subscribe for More Information
16:00 EDTBACOptions Update; September 8, 2014
Subscribe for More Information
14:13 EDTAZNConnecticut AG tells FDA to speed up generic Nexium
A news release from the Connecticut Attorney General George Jepsen, dated September 4, says: In comments to a Citizen Petition filed with the FDA, Attorney General George Jepsen called on the federal agency to expeditiously end several years of delays preventing the sale of a generic form of the drug esomeprazole magnesium , esomeprazole, currently marketed under the brand name Nexium. Nexium is the second highest-selling pharmaceutical drug in the United States, and delays in approving generic versions have cost consumers and government healthcare payers billions of dollars. In his comments, Attorney General Jepsen alleges that an agreement between drug manufacturers Ranbaxy (RBXLY) and AstraZeneca Pharmaceuticals (AZN), Nexiumís brand-name manufacturer, has prevented other drug-makers from launching a generic version of the drug, ultimately harming all consumers by artificially inflating prices. Ranbaxy was first-to-file with the FDA for approval of a generic form of Nexium. AstraZeneca sued Ranbaxy for patent infringement, and the dispute was settled by an agreement that provided financial incentives for Ranbaxy to delay entry of its generic into the consumer market. Reference Link
12:18 EDTGEOn The Fly: Midday Wrap
Subscribe for More Information
11:04 EDTGEGeneral Electric to host investor meeting
Subscribe for More Information
10:48 EDTBACBank of America upgraded as legal issues recede
Subscribe for More Information
10:06 EDTBACOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:40 EDTBACActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
08:18 EDTGEElectrolux sees GE Appliances transaction accretive to EPS in year one
Subscribe for More Information
08:03 EDTGEGeneral Electric, Accenture launch Intelligent Pipeline Solution
Subscribe for More Information
07:15 EDTPFEIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:02 EDTAZNAstraZeneca announces availability of Bydureon pen 2mg
Subscribe for More Information
06:59 EDTCMCSA, TWCTWC workers to split $416M if Comcast deal falls through, Reuters says
In order to keep employees from leaving while federal regulators mull the final agreement, Time Warner Cable (TWC) workers will split $416M if the company's merger deal with Comcast (CMCSA) does not transpire, according to Reuters, citing a proxy statement. Reference Link
06:25 EDTGEAlstom unit accused of bribing officials EUR6M to win contracts, FT reports
Subscribe for More Information
06:20 EDTTWC, CMCSADiscovery: Comcast-TWC merger gives unfair advantage, NY Post reports
Discovery (DISCA) said Comcast's (CMCSA) takeover of Time Warner Cable (TWC) could give the combined company an unfair advantage over programmers, reports the New York Post. Discovery said the the company would have an advantage in carriage negotiations and in the advertising realms by refusing to share set-top-box data with programmers. Reference Link
05:40 EDTBACBank of America upgraded to Buy from Neutral at Goldman
Goldman Sachs upgraded its rating on Bank of America (BAC) shares to Buy citing the resolution of a lot of the bank's legal issues and the shift of its earnings mix towards higher growth businesses. Goldman raised its price target for shares to $19 from $17. Bank of America closed Friday down 9c to $16.02.
05:32 EDTGEGeneral Electric to sell appliances business to Electrolux AB for $3.3B
Subscribe for More Information
05:29 EDTGEGeneral Electric to sell appliances business to Electrolux AB for $3.3B
Subscribe for More Information
September 7, 2014
15:52 EDTGEGE's oil and gas unit set to outpace industry growth, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use